<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285518</url>
  </required_header>
  <id_info>
    <org_study_id>B2901001</org_study_id>
    <nct_id>NCT01285518</nct_id>
  </id_info>
  <brief_title>Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Intravenous Doses Of Pf-05231023 In Adult Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability
      and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Physical Examination Findings</measure>
    <time_frame>Day -1 up to Day 22</time_frame>
    <description>Physical examination included assessment of height, weight, blood pressure and pulse rate. Criteria for abnormal physical findings was based on investigator's discretion and were reported as adverse event (AE), as planned.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 up to Day 22</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 22 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values</measure>
    <time_frame>Day -1 up to Day 15</time_frame>
    <description>Criteria for laboratory tests abnormalities included: hemoglobin, hematocrit and red blood cells (RBCs)(less than [&lt;] 0.8*lower limit of normal[LLN]); leucocytes (&lt;0.6/greater than [&gt;]1.5*upper limit of normal [ULN]); platelets (&lt;0.5*LLN/&gt;1.75*ULN); neutrophils, lymphocytes (&lt;0.8*LLN/&gt;1.2*ULN); eosinophils, basophils, monocytes (&gt;1.2*ULN); total bilirubin, direct bilirubin, indirect bilirubin (&gt;1.5*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (&gt;3*ULN), total protein, albumin (&lt;0.8*LLN/&gt;1.2*ULN); creatinine, urea (&gt;1.3*ULN); glucose (&lt;0.6*LLN/&gt;1.5*ULN); uric acid (&gt;1.2*ULN); sodium, potassium, chloride, calcium, bicarbonate (&lt;0.9*LLN/&gt;1.1*ULN); urine RBCs, urine white blood cells (WBCs) (&gt; or equal[=]20 high-powered field), urine bacteria &gt;20 high-powered field. Total number of participants with any laboratory abnormalities was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs Abnormalities</measure>
    <time_frame>Day 1 up to Day 15</time_frame>
    <description>Criteria for vital signs abnormalities: supine systolic blood pressure (SBP) &lt;90 millimeter of mercury (mmHg), supine diastolic BP (DBP) &lt;50 mmHg, supine pulse rate &lt;40 beats per minute (bpm). Maximum increase or decrease from baseline in supine SBP &gt;=30 mmHg and maximum increase or decrease from baseline in supine DBP &gt;=20 mmHg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Screening up to Day 15</time_frame>
    <description>Criteria for potential clinical concern in ECG parameters: maximum PR interval of greater than or equal to (&gt;=) 300 milliseconds (msec), maximum QRS interval &gt;=140 msec, maximum QTCF interval (Fridericia's Correction) of 450 to &lt;480 msec, 480 to &lt;500 msec and &gt;=500 msec, maximum increase of &gt;=25 percent (%) for baseline value of &gt;200 msec for PR interval and maximum increase of &gt;=50% for baseline value of less than or equal to (&lt;=) 200 msec for QRS interval, maximum increase from baseline of &gt;=30 msec to &lt;60 msec and maximum increase from baseline of &gt;60 msec in QTCF interval (Fridericia's Correction).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Hypoglycemic Adverse Event Based on Capillary Glucose Levels</measure>
    <time_frame>Day 0 up to Day 22</time_frame>
    <description>Capillary blood glucose levels were collected to observe any hypoglycemic adverse events. Hypoglycemia was assessed as following categories; Severe hypoglycemia (1. Participant was unable to treat himself/herself, requiring assistance of another person to actively administer carbohydrate, glucagon 2. Exhibited one of following neurological symptoms memory loss, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure or loss of consciousness, 3. Glucose &lt;50 mg/dL confirmed on repeat measure); Documented symptomatic hypoglycemia (1. Symptoms of hypoglycaemia accompanied by a measured glucose concentration &lt;=70 mg/dL); asymptomatic hypoglycemia (not accompanied by typical symptoms of hypoglycaemia but with a measured glucose concentration &lt;=70 mg/dL), and probable hypoglycemia (typical symptoms of hypoglycaemia are not accompanied by a glucose determination, but was presumably caused by a plasma glucose concentration &lt;=70 mg/dL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Blood Glucose Abnormalities</measure>
    <time_frame>Day -1 up to Day 15</time_frame>
    <description>Criteria for blood glucose abnormality: Blood glucose levels &lt;0.6*lower limit of normal (LLN) or &gt;1.5*upper limit of normal (ULN).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-Drug Antibodies (ADA): Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-Drug Antibodies (ADA): Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-Drug Antibodies (ADA): Day 15</measure>
    <time_frame>Day 15</time_frame>
    <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-Drug Antibodies (ADA): Day 22</measure>
    <time_frame>Day 22</time_frame>
    <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-Drug Antibodies (ADA): Day 34</measure>
    <time_frame>Day 34</time_frame>
    <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich (enzyme-linked immunosorbent assay) ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 2</measure>
    <time_frame>Day 2</time_frame>
    <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 5</measure>
    <time_frame>Day 5</time_frame>
    <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 15</measure>
    <time_frame>Day 15</time_frame>
    <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 2</measure>
    <time_frame>Day 2</time_frame>
    <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 5</measure>
    <time_frame>Day 5</time_frame>
    <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 15</measure>
    <time_frame>Day 15</time_frame>
    <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Cardiac Rhythms Recorded by Telemetry</measure>
    <time_frame>From 2 hours (H) pre-dose for intravenous bolus or 2 H prior to the start of infusion on Day 1 up to 8 H post-dose for bolus or 8 H following the end of the infusion on Day 1</time_frame>
    <description>Criteria for abnormal cardiac rhythms was based on investigator's discretion and were reported as adverse event (AE), as planned.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Time of Last Quantifiable Plasma Concentration (AUClast) of PF-05231023</measure>
    <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
Participants who received PF-05231023 with C-terminal and N-terminal AUClast were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05231023</measure>
    <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
    <description>Participants who received PF-05231023 with C-terminal and N-terminal Tmax were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of PF-05231023</measure>
    <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
    <description>Participants who received PF-05231023 with C-terminal and N-terminal Cmax were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Terminal Half-Life (t1/2) of PF-05231023</measure>
    <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
    <description>Plasma terminal half-life is the time measured for the plasma concentration to decrease by one half at the terminal phase. Participants who received PF-05231023 with C-terminal and N-terminal t1/2 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL) of PF-05231023 for Intravenous Bolus Dosing</measure>
    <time_frame>Hour (H)-1 (1 H pre-dose to bolus [Bo]),H-0.5(0.5 H pre-dose to Bo),H 0 (prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.Participants who received PF-05231023 with C-terminal and N-terminal CL were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz) of PF-05231023</measure>
    <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. PF-05231023 with C-terminal and N-terminal Vz were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-05231023</measure>
    <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
    <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). PF-05231023 with C-terminal and N-terminal AUC (0 - ∞) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back-extrapolated Concentration at Time Zero (C0) of PF-05231023</measure>
    <time_frame>0.25 H post-dose to Bo on Day 1</time_frame>
    <description>C0 was estimated by back-extrapolating from the first 2 concentration values using the log-linear regression on the first 2 data points (where second concentration was less than [&lt;] first concentration) to back-extrapolate C0. PF-05231023 with C-terminal and N-terminal C0 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of PF-05231023</measure>
    <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
    <description>Vss was calculated by dividing the area under the first moment curve from time zero to infinity [AUMC(0-∞)] with the product of area under the curve from time zero to extrapolated infinite time [AUC (0 - ∞)] and apparent clearance (CL). PF-05231023 with C-terminal and N-terminal Vss were reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% w/v sodium chloride injection, USP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05231023</intervention_name>
    <description>0.5 mg QD IV x 1 day</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05231023</intervention_name>
    <description>1.5 mg QD IV x 1 day</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05231023</intervention_name>
    <description>5 mg QD IV x 1 day</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05231023</intervention_name>
    <description>15 mg QD IV x 1 day</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05231023</intervention_name>
    <description>50 mg QD IV x 1 day</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05231023</intervention_name>
    <description>100 mg QD IV x 1 day</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05231023</intervention_name>
    <description>200 mg QD IV x 1 day</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% w/v sodium chloride injection, USP QD IVx 1 day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects between the ages of 30 and 65 years, inclusive, with a
             historical diagnosis of type 2 diabetes mellitus, diagnosed according to the American
             Diabetes Association guidelines.

          -  Body Mass Index (BMI) of 25 to 35.5 kg/m2, and a total body weight &gt;50 kg (110 lbs).

          -  HbA1c &gt;7% and not to exceed 10.5%.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Diagnosis of Type 1 diabetes mellitus

          -  Evidence of diabetic complications with significant end organ damage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.)</name>
      <address>
        <city>Ft. Meyers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.)</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2901001&amp;StudyName=Safety%20And%20Tolerability%20Of%20Escalating%20Intravenous%20Doses%20Of%20PF-05231023%20In%20Adult%20Subjects%20With%20Type%202%20Diabetes</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2011</study_first_posted>
  <results_first_submitted>December 18, 2014</results_first_submitted>
  <results_first_submitted_qc>September 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2016</results_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>intravenous</keyword>
  <keyword>single dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with a historical diagnosis of type 2 diabetes mellitus (T2DM), diagnosed according to the American Diabetes Association (ADA) guidelines and those with well-controlled diabetes were recruited in the study.</recruitment_details>
      <pre_assignment_details>Dose of PF-05231023 was escalated based on sponsor’s and investigator’s discretion, depending upon safety, tolerability and pharmacokinetic profile of PF-05231023.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PF-05231023 0.5 mg</title>
          <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>PF-05231023 1.5 mg</title>
          <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>PF-05231023 5 mg</title>
          <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>PF-05231023 15 mg</title>
          <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>PF-05231023 50 mg</title>
          <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>PF-05231023 100 mg</title>
          <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>PF-05231023 200 mg</title>
          <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="P8">
          <title>Placebo</title>
          <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis population included all participants who received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>PF-05231023 0.5 mg</title>
          <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>PF-05231023 1.5 mg</title>
          <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>PF-05231023 5 mg</title>
          <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>PF-05231023 15 mg</title>
          <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>PF-05231023 50 mg</title>
          <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>PF-05231023 100 mg</title>
          <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>PF-05231023 200 mg</title>
          <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Placebo</title>
          <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="10"/>
            <count group_id="B8" value="14"/>
            <count group_id="B9" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" spread="4.1"/>
                    <measurement group_id="B2" value="58.4" spread="3.9"/>
                    <measurement group_id="B3" value="53.8" spread="7.2"/>
                    <measurement group_id="B4" value="53.3" spread="8.2"/>
                    <measurement group_id="B5" value="54.5" spread="8.6"/>
                    <measurement group_id="B6" value="55.2" spread="7.3"/>
                    <measurement group_id="B7" value="57.2" spread="5.7"/>
                    <measurement group_id="B8" value="52.9" spread="6.8"/>
                    <measurement group_id="B9" value="55.5" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Physical Examination Findings</title>
        <description>Physical examination included assessment of height, weight, blood pressure and pulse rate. Criteria for abnormal physical findings was based on investigator’s discretion and were reported as adverse event (AE), as planned.</description>
        <time_frame>Day -1 up to Day 22</time_frame>
        <population>Data was not collected since this outcome measure was not analyzed as per Sponsor’s discretion.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Physical Examination Findings</title>
          <description>Physical examination included assessment of height, weight, blood pressure and pulse rate. Criteria for abnormal physical findings was based on investigator’s discretion and were reported as adverse event (AE), as planned.</description>
          <population>Data was not collected since this outcome measure was not analyzed as per Sponsor’s discretion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 22 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
        <time_frame>Day 1 up to Day 22</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 22 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Laboratory Values</title>
        <description>Criteria for laboratory tests abnormalities included: hemoglobin, hematocrit and red blood cells (RBCs)(less than [&lt;] 0.8*lower limit of normal[LLN]); leucocytes (&lt;0.6/greater than [&gt;]1.5*upper limit of normal [ULN]); platelets (&lt;0.5*LLN/&gt;1.75*ULN); neutrophils, lymphocytes (&lt;0.8*LLN/&gt;1.2*ULN); eosinophils, basophils, monocytes (&gt;1.2*ULN); total bilirubin, direct bilirubin, indirect bilirubin (&gt;1.5*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (&gt;3*ULN), total protein, albumin (&lt;0.8*LLN/&gt;1.2*ULN); creatinine, urea (&gt;1.3*ULN); glucose (&lt;0.6*LLN/&gt;1.5*ULN); uric acid (&gt;1.2*ULN); sodium, potassium, chloride, calcium, bicarbonate (&lt;0.9*LLN/&gt;1.1*ULN); urine RBCs, urine white blood cells (WBCs) (&gt; or equal[=]20 high-powered field), urine bacteria &gt;20 high-powered field. Total number of participants with any laboratory abnormalities was reported.</description>
        <time_frame>Day -1 up to Day 15</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Laboratory Values</title>
          <description>Criteria for laboratory tests abnormalities included: hemoglobin, hematocrit and red blood cells (RBCs)(less than [&lt;] 0.8*lower limit of normal[LLN]); leucocytes (&lt;0.6/greater than [&gt;]1.5*upper limit of normal [ULN]); platelets (&lt;0.5*LLN/&gt;1.75*ULN); neutrophils, lymphocytes (&lt;0.8*LLN/&gt;1.2*ULN); eosinophils, basophils, monocytes (&gt;1.2*ULN); total bilirubin, direct bilirubin, indirect bilirubin (&gt;1.5*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (&gt;3*ULN), total protein, albumin (&lt;0.8*LLN/&gt;1.2*ULN); creatinine, urea (&gt;1.3*ULN); glucose (&lt;0.6*LLN/&gt;1.5*ULN); uric acid (&gt;1.2*ULN); sodium, potassium, chloride, calcium, bicarbonate (&lt;0.9*LLN/&gt;1.1*ULN); urine RBCs, urine white blood cells (WBCs) (&gt; or equal[=]20 high-powered field), urine bacteria &gt;20 high-powered field. Total number of participants with any laboratory abnormalities was reported.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs Abnormalities</title>
        <description>Criteria for vital signs abnormalities: supine systolic blood pressure (SBP) &lt;90 millimeter of mercury (mmHg), supine diastolic BP (DBP) &lt;50 mmHg, supine pulse rate &lt;40 beats per minute (bpm). Maximum increase or decrease from baseline in supine SBP &gt;=30 mmHg and maximum increase or decrease from baseline in supine DBP &gt;=20 mmHg.</description>
        <time_frame>Day 1 up to Day 15</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs Abnormalities</title>
          <description>Criteria for vital signs abnormalities: supine systolic blood pressure (SBP) &lt;90 millimeter of mercury (mmHg), supine diastolic BP (DBP) &lt;50 mmHg, supine pulse rate &lt;40 beats per minute (bpm). Maximum increase or decrease from baseline in supine SBP &gt;=30 mmHg and maximum increase or decrease from baseline in supine DBP &gt;=20 mmHg.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine SBP &lt;90 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate &lt;40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine SBP: Maximum increase &gt;=30 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP: Maximum increase &gt;=20 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine SBP: Maximum decrease &gt;=30 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP: Maximum decrease &gt;=20 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Electrocardiogram (ECG) Abnormalities</title>
        <description>Criteria for potential clinical concern in ECG parameters: maximum PR interval of greater than or equal to (&gt;=) 300 milliseconds (msec), maximum QRS interval &gt;=140 msec, maximum QTCF interval (Fridericia’s Correction) of 450 to &lt;480 msec, 480 to &lt;500 msec and &gt;=500 msec, maximum increase of &gt;=25 percent (%) for baseline value of &gt;200 msec for PR interval and maximum increase of &gt;=50% for baseline value of less than or equal to (&lt;=) 200 msec for QRS interval, maximum increase from baseline of &gt;=30 msec to &lt;60 msec and maximum increase from baseline of &gt;60 msec in QTCF interval (Fridericia’s Correction).</description>
        <time_frame>Screening up to Day 15</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiogram (ECG) Abnormalities</title>
          <description>Criteria for potential clinical concern in ECG parameters: maximum PR interval of greater than or equal to (&gt;=) 300 milliseconds (msec), maximum QRS interval &gt;=140 msec, maximum QTCF interval (Fridericia’s Correction) of 450 to &lt;480 msec, 480 to &lt;500 msec and &gt;=500 msec, maximum increase of &gt;=25 percent (%) for baseline value of &gt;200 msec for PR interval and maximum increase of &gt;=50% for baseline value of less than or equal to (&lt;=) 200 msec for QRS interval, maximum increase from baseline of &gt;=30 msec to &lt;60 msec and maximum increase from baseline of &gt;60 msec in QTCF interval (Fridericia’s Correction).</description>
          <population>Safety population included all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximum PR interval &gt;=300 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QRS Complex &gt;=140 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTCF interval 450 to &lt;480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTCF interval 480 to &lt;500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTCF interval &gt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval increase from baseline &gt;=25/50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS complex increase from baseline &gt;=50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF interval increase from baseline 30 to 60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF interval increase from baseline &gt;=60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hypoglycemic Adverse Event Based on Capillary Glucose Levels</title>
        <description>Capillary blood glucose levels were collected to observe any hypoglycemic adverse events. Hypoglycemia was assessed as following categories; Severe hypoglycemia (1. Participant was unable to treat himself/herself, requiring assistance of another person to actively administer carbohydrate, glucagon 2. Exhibited one of following neurological symptoms memory loss, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure or loss of consciousness, 3. Glucose &lt;50 mg/dL confirmed on repeat measure); Documented symptomatic hypoglycemia (1. Symptoms of hypoglycaemia accompanied by a measured glucose concentration &lt;=70 mg/dL); asymptomatic hypoglycemia (not accompanied by typical symptoms of hypoglycaemia but with a measured glucose concentration &lt;=70 mg/dL), and probable hypoglycemia (typical symptoms of hypoglycaemia are not accompanied by a glucose determination, but was presumably caused by a plasma glucose concentration &lt;=70 mg/dL).</description>
        <time_frame>Day 0 up to Day 22</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypoglycemic Adverse Event Based on Capillary Glucose Levels</title>
          <description>Capillary blood glucose levels were collected to observe any hypoglycemic adverse events. Hypoglycemia was assessed as following categories; Severe hypoglycemia (1. Participant was unable to treat himself/herself, requiring assistance of another person to actively administer carbohydrate, glucagon 2. Exhibited one of following neurological symptoms memory loss, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure or loss of consciousness, 3. Glucose &lt;50 mg/dL confirmed on repeat measure); Documented symptomatic hypoglycemia (1. Symptoms of hypoglycaemia accompanied by a measured glucose concentration &lt;=70 mg/dL); asymptomatic hypoglycemia (not accompanied by typical symptoms of hypoglycaemia but with a measured glucose concentration &lt;=70 mg/dL), and probable hypoglycemia (typical symptoms of hypoglycaemia are not accompanied by a glucose determination, but was presumably caused by a plasma glucose concentration &lt;=70 mg/dL).</description>
          <population>Safety population included all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable Symptomatic Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Blood Glucose Abnormalities</title>
        <description>Criteria for blood glucose abnormality: Blood glucose levels &lt;0.6*lower limit of normal (LLN) or &gt;1.5*upper limit of normal (ULN).</description>
        <time_frame>Day -1 up to Day 15</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Blood Glucose Abnormalities</title>
          <description>Criteria for blood glucose abnormality: Blood glucose levels &lt;0.6*lower limit of normal (LLN) or &gt;1.5*upper limit of normal (ULN).</description>
          <population>Safety population included all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;0.6*LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-Drug Antibodies (ADA): Day 1</title>
        <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
        <time_frame>Day 1</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication. No participant in the placebo group was assessed for this time point of outcome measure, hence results were not reported for the same.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibodies (ADA): Day 1</title>
          <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication. No participant in the placebo group was assessed for this time point of outcome measure, hence results were not reported for the same.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-Drug Antibodies (ADA): Day 8</title>
        <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
        <time_frame>Day 8</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication. No participant in the placebo group was assessed for this time point of outcome measure, hence results were not reported for the same.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibodies (ADA): Day 8</title>
          <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication. No participant in the placebo group was assessed for this time point of outcome measure, hence results were not reported for the same.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-Drug Antibodies (ADA): Day 15</title>
        <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
        <time_frame>Day 15</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication. No participant in the placebo group was assessed for this time point of outcome measure, hence results were not reported for the same. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibodies (ADA): Day 15</title>
          <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication. No participant in the placebo group was assessed for this time point of outcome measure, hence results were not reported for the same. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-Drug Antibodies (ADA): Day 22</title>
        <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
        <time_frame>Day 22</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibodies (ADA): Day 22</title>
          <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-Drug Antibodies (ADA): Day 34</title>
        <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
        <time_frame>Day 34</time_frame>
        <population>Safety population. No participant was involved in groups: PF-05231023 0.5,1.5,5,15,50,100 mg and placebo for this time point of outcome measure, hence results were not reported for the same.'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibodies (ADA): Day 34</title>
          <description>Assays for the determination of human anti-drug (Anti-PF-05231023) antibodies (ADA) was performed.</description>
          <population>Safety population. No participant was involved in groups: PF-05231023 0.5,1.5,5,15,50,100 mg and placebo for this time point of outcome measure, hence results were not reported for the same.'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 1</title>
        <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich (enzyme-linked immunosorbent assay) ELISA method.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 1</title>
          <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich (enzyme-linked immunosorbent assay) ELISA method.</description>
          <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IGF-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.2" spread="69.33"/>
                    <measurement group_id="O2" value="142.3" spread="47.10"/>
                    <measurement group_id="O3" value="143.4" spread="42.80"/>
                    <measurement group_id="O4" value="146.8" spread="50.97"/>
                    <measurement group_id="O5" value="128.4" spread="35.44"/>
                    <measurement group_id="O6" value="135.7" spread="59.12"/>
                    <measurement group_id="O7" value="153.1" spread="51.57"/>
                    <measurement group_id="O8" value="131.3" spread="34.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="1.414"/>
                    <measurement group_id="O2" value="1.02" spread="0.525"/>
                    <measurement group_id="O3" value="2.63" spread="2.954"/>
                    <measurement group_id="O4" value="2.81" spread="2.454"/>
                    <measurement group_id="O5" value="1.20" spread="0.995"/>
                    <measurement group_id="O6" value="2.23" spread="3.138"/>
                    <measurement group_id="O7" value="2.88" spread="1.724"/>
                    <measurement group_id="O8" value="1.69" spread="1.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.5" spread="109.33"/>
                    <measurement group_id="O2" value="134.2" spread="50.00"/>
                    <measurement group_id="O3" value="143.8" spread="48.44"/>
                    <measurement group_id="O4" value="197.1" spread="147.01"/>
                    <measurement group_id="O5" value="108.8" spread="39.77"/>
                    <measurement group_id="O6" value="147.9" spread="89.58"/>
                    <measurement group_id="O7" value="204.7" spread="122.70"/>
                    <measurement group_id="O8" value="146.7" spread="79.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.178" spread="0.2981"/>
                    <measurement group_id="O2" value="0.121" spread="0.1521"/>
                    <measurement group_id="O3" value="0.133" spread="0.1629"/>
                    <measurement group_id="O4" value="0.222" spread="0.2189"/>
                    <measurement group_id="O5" value="0.316" spread="0.4162"/>
                    <measurement group_id="O6" value="0.296" spread="0.5557"/>
                    <measurement group_id="O7" value="0.448" spread="0.5928"/>
                    <measurement group_id="O8" value="0.079" spread="0.0355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 2</title>
        <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
        <time_frame>Day 2</time_frame>
        <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 2</title>
          <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
          <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IGF-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.1" spread="75.35"/>
                    <measurement group_id="O2" value="148.0" spread="47.00"/>
                    <measurement group_id="O3" value="163.5" spread="50.79"/>
                    <measurement group_id="O4" value="152.9" spread="51.08"/>
                    <measurement group_id="O5" value="145.0" spread="63.28"/>
                    <measurement group_id="O6" value="154.9" spread="55.30"/>
                    <measurement group_id="O7" value="168.4" spread="58.24"/>
                    <measurement group_id="O8" value="135.7" spread="33.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="2.068"/>
                    <measurement group_id="O2" value="2.68" spread="1.570"/>
                    <measurement group_id="O3" value="2.37" spread="2.489"/>
                    <measurement group_id="O4" value="4.37" spread="4.093"/>
                    <measurement group_id="O5" value="2.67" spread="1.830"/>
                    <measurement group_id="O6" value="2.41" spread="1.711"/>
                    <measurement group_id="O7" value="4.49" spread="2.824"/>
                    <measurement group_id="O8" value="3.01" spread="2.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.1" spread="80.23"/>
                    <measurement group_id="O2" value="130.2" spread="43.42"/>
                    <measurement group_id="O3" value="154.4" spread="47.72"/>
                    <measurement group_id="O4" value="200.7" spread="171.17"/>
                    <measurement group_id="O5" value="117.7" spread="41.88"/>
                    <measurement group_id="O6" value="174.1" spread="104.64"/>
                    <measurement group_id="O7" value="212.6" spread="137.72"/>
                    <measurement group_id="O8" value="160.1" spread="87.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.230" spread="0.3135"/>
                    <measurement group_id="O2" value="0.369" spread="0.7146"/>
                    <measurement group_id="O3" value="0.182" spread="0.2109"/>
                    <measurement group_id="O4" value="0.386" spread="0.3823"/>
                    <measurement group_id="O5" value="0.316" spread="0.3116"/>
                    <measurement group_id="O6" value="0.407" spread="0.4363"/>
                    <measurement group_id="O7" value="0.620" spread="0.4641"/>
                    <measurement group_id="O8" value="0.498" spread="0.8284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 3</title>
        <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
        <time_frame>Day 3</time_frame>
        <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 3</title>
          <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
          <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
          <units>nanogram per millileter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IGF-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.1" spread="62.82"/>
                    <measurement group_id="O2" value="147.5" spread="45.10"/>
                    <measurement group_id="O3" value="158.6" spread="46.26"/>
                    <measurement group_id="O4" value="164.2" spread="57.90"/>
                    <measurement group_id="O5" value="156.3" spread="75.73"/>
                    <measurement group_id="O6" value="149.8" spread="57.41"/>
                    <measurement group_id="O7" value="178.5" spread="53.85"/>
                    <measurement group_id="O8" value="137.7" spread="33.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="1.910"/>
                    <measurement group_id="O2" value="2.57" spread="1.947"/>
                    <measurement group_id="O3" value="2.38" spread="2.863"/>
                    <measurement group_id="O4" value="3.00" spread="2.682"/>
                    <measurement group_id="O5" value="4.27" spread="4.803"/>
                    <measurement group_id="O6" value="2.70" spread="3.519"/>
                    <measurement group_id="O7" value="3.10" spread="1.694"/>
                    <measurement group_id="O8" value="2.00" spread="1.393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.4" spread="106.14"/>
                    <measurement group_id="O2" value="135.7" spread="47.46"/>
                    <measurement group_id="O3" value="144.4" spread="43.00"/>
                    <measurement group_id="O4" value="188.2" spread="138.45"/>
                    <measurement group_id="O5" value="129.1" spread="42.61"/>
                    <measurement group_id="O6" value="155.0" spread="99.66"/>
                    <measurement group_id="O7" value="223.3" spread="120.05"/>
                    <measurement group_id="O8" value="145.2" spread="61.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.186" spread="0.2030"/>
                    <measurement group_id="O2" value="0.192" spread="0.1165"/>
                    <measurement group_id="O3" value="0.273" spread="0.3549"/>
                    <measurement group_id="O4" value="0.312" spread="0.3008"/>
                    <measurement group_id="O5" value="0.432" spread="0.6493"/>
                    <measurement group_id="O6" value="0.406" spread="0.3544"/>
                    <measurement group_id="O7" value="0.588" spread="0.4084"/>
                    <measurement group_id="O8" value="0.169" spread="0.1647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 5</title>
        <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
        <time_frame>Day 5</time_frame>
        <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 5</title>
          <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
          <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
          <units>nanogram per millileter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IGF-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.4" spread="74.86"/>
                    <measurement group_id="O2" value="156.1" spread="40.03"/>
                    <measurement group_id="O3" value="152.7" spread="48.18"/>
                    <measurement group_id="O4" value="155.4" spread="54.29"/>
                    <measurement group_id="O5" value="136.9" spread="54.82"/>
                    <measurement group_id="O6" value="143.6" spread="54.03"/>
                    <measurement group_id="O7" value="163.6" spread="44.96"/>
                    <measurement group_id="O8" value="137.0" spread="27.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="2.186"/>
                    <measurement group_id="O2" value="2.36" spread="1.629"/>
                    <measurement group_id="O3" value="2.61" spread="2.497"/>
                    <measurement group_id="O4" value="2.93" spread="2.547"/>
                    <measurement group_id="O5" value="4.02" spread="4.484"/>
                    <measurement group_id="O6" value="2.64" spread="3.102"/>
                    <measurement group_id="O7" value="3.11" spread="1.805"/>
                    <measurement group_id="O8" value="2.31" spread="2.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.1" spread="101.02"/>
                    <measurement group_id="O2" value="129.4" spread="44.14"/>
                    <measurement group_id="O3" value="152.4" spread="61.19"/>
                    <measurement group_id="O4" value="193.1" spread="137.11"/>
                    <measurement group_id="O5" value="135.5" spread="43.32"/>
                    <measurement group_id="O6" value="156.1" spread="117.61"/>
                    <measurement group_id="O7" value="207.9" spread="97.73"/>
                    <measurement group_id="O8" value="150.1" spread="69.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.190" spread="0.2492"/>
                    <measurement group_id="O2" value="0.146" spread="0.0802"/>
                    <measurement group_id="O3" value="0.169" spread="0.1788"/>
                    <measurement group_id="O4" value="0.233" spread="0.1884"/>
                    <measurement group_id="O5" value="0.271" spread="0.3159"/>
                    <measurement group_id="O6" value="0.188" spread="0.1641"/>
                    <measurement group_id="O7" value="0.484" spread="0.4962"/>
                    <measurement group_id="O8" value="0.216" spread="0.2418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 7</title>
        <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
        <time_frame>Day 7</time_frame>
        <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint. Here,'n' signifies participants who were evaluable at each specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 7</title>
          <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
          <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint. Here,'n' signifies participants who were evaluable at each specified time point for each arm, respectively.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IGF-1 (n=10,10,10,10,10,10,10,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.1" spread="73.55"/>
                    <measurement group_id="O2" value="151.0" spread="47.72"/>
                    <measurement group_id="O3" value="152.3" spread="54.13"/>
                    <measurement group_id="O4" value="157.1" spread="61.32"/>
                    <measurement group_id="O5" value="130.4" spread="55.44"/>
                    <measurement group_id="O6" value="143.9" spread="59.06"/>
                    <measurement group_id="O7" value="154.1" spread="41.88"/>
                    <measurement group_id="O8" value="132.5" spread="28.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-1 (n=10,10,10,10,10,9,10,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="3.533"/>
                    <measurement group_id="O2" value="2.77" spread="2.113"/>
                    <measurement group_id="O3" value="3.03" spread="3.261"/>
                    <measurement group_id="O4" value="2.98" spread="3.948"/>
                    <measurement group_id="O5" value="2.61" spread="2.348"/>
                    <measurement group_id="O6" value="2.80" spread="3.440"/>
                    <measurement group_id="O7" value="3.39" spread="1.824"/>
                    <measurement group_id="O8" value="3.46" spread="4.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-2 (n=10,10,10,10,10,9,10,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.7" spread="107.34"/>
                    <measurement group_id="O2" value="116.5" spread="30.62"/>
                    <measurement group_id="O3" value="166.4" spread="48.32"/>
                    <measurement group_id="O4" value="178.7" spread="126.83"/>
                    <measurement group_id="O5" value="132.8" spread="46.18"/>
                    <measurement group_id="O6" value="173.8" spread="148.78"/>
                    <measurement group_id="O7" value="229.8" spread="118.94"/>
                    <measurement group_id="O8" value="154.7" spread="88.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GH (n=10,10,10,10,10,10,10,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.233" spread="0.2506"/>
                    <measurement group_id="O2" value="0.112" spread="0.0738"/>
                    <measurement group_id="O3" value="0.108" spread="0.0760"/>
                    <measurement group_id="O4" value="0.254" spread="0.3971"/>
                    <measurement group_id="O5" value="0.142" spread="0.1003"/>
                    <measurement group_id="O6" value="0.120" spread="0.1067"/>
                    <measurement group_id="O7" value="0.320" spread="0.1942"/>
                    <measurement group_id="O8" value="0.201" spread="0.2193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 15</title>
        <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
        <time_frame>Day 15</time_frame>
        <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. 'n' signifies participants who were evaluable for each specified parameter for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 15</title>
          <description>Plasma samples for IGF-1, and GH were analyzed using a validated, sensitive, and specific immunochromatographic membrane assay (ICMA) fluorescence method. Plasma samples for IGFBP-1, IGFBP-2 were assayed using a validated, sensitive, and specific colorimetric sandwich ELISA method.</description>
          <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. 'n' signifies participants who were evaluable for each specified parameter for each arm, respectively.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IGF-1 (n=10,10,9,10,10,9,9,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.7" spread="55.26"/>
                    <measurement group_id="O2" value="132.6" spread="42.72"/>
                    <measurement group_id="O3" value="116.7" spread="38.99"/>
                    <measurement group_id="O4" value="131.2" spread="45.53"/>
                    <measurement group_id="O5" value="106.2" spread="44.50"/>
                    <measurement group_id="O6" value="123.2" spread="51.08"/>
                    <measurement group_id="O7" value="126.3" spread="40.32"/>
                    <measurement group_id="O8" value="112.5" spread="25.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-1 (n=10,10,9,10,10,9,9,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="1.999"/>
                    <measurement group_id="O2" value="2.59" spread="1.573"/>
                    <measurement group_id="O3" value="2.90" spread="3.357"/>
                    <measurement group_id="O4" value="2.28" spread="2.262"/>
                    <measurement group_id="O5" value="2.70" spread="2.186"/>
                    <measurement group_id="O6" value="3.23" spread="3.567"/>
                    <measurement group_id="O7" value="3.36" spread="2.261"/>
                    <measurement group_id="O8" value="2.11" spread="1.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-2 (n=10,10,9,10,10,9,9,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.6" spread="89.55"/>
                    <measurement group_id="O2" value="154.7" spread="38.39"/>
                    <measurement group_id="O3" value="157.3" spread="60.35"/>
                    <measurement group_id="O4" value="240.8" spread="177.76"/>
                    <measurement group_id="O5" value="155.4" spread="49.16"/>
                    <measurement group_id="O6" value="193.1" spread="145.98"/>
                    <measurement group_id="O7" value="247.3" spread="145.61"/>
                    <measurement group_id="O8" value="181.6" spread="129.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GH (n=10,10,9,10,10,9,9,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.216" spread="0.2557"/>
                    <measurement group_id="O2" value="0.135" spread="0.1039"/>
                    <measurement group_id="O3" value="0.133" spread="0.1111"/>
                    <measurement group_id="O4" value="0.115" spread="0.0920"/>
                    <measurement group_id="O5" value="0.090" spread="0.0927"/>
                    <measurement group_id="O6" value="0.161" spread="0.1388"/>
                    <measurement group_id="O7" value="0.183" spread="0.2236"/>
                    <measurement group_id="O8" value="0.180" spread="0.1628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 1</title>
        <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 1</title>
          <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
          <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="1.028"/>
                    <measurement group_id="O2" value="4.03" spread="1.325"/>
                    <measurement group_id="O3" value="3.80" spread="1.026"/>
                    <measurement group_id="O4" value="3.47" spread="0.804"/>
                    <measurement group_id="O5" value="3.52" spread="1.260"/>
                    <measurement group_id="O6" value="3.44" spread="1.198"/>
                    <measurement group_id="O7" value="3.52" spread="1.003"/>
                    <measurement group_id="O8" value="3.66" spread="0.925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 2</title>
        <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
        <time_frame>Day 2</time_frame>
        <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 2</title>
          <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
          <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" spread="0.983"/>
                    <measurement group_id="O2" value="4.04" spread="1.211"/>
                    <measurement group_id="O3" value="3.78" spread="0.887"/>
                    <measurement group_id="O4" value="3.49" spread="0.839"/>
                    <measurement group_id="O5" value="3.79" spread="1.440"/>
                    <measurement group_id="O6" value="3.53" spread="1.069"/>
                    <measurement group_id="O7" value="3.53" spread="0.888"/>
                    <measurement group_id="O8" value="3.63" spread="0.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 3</title>
        <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
        <time_frame>Day 3</time_frame>
        <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 3</title>
          <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
          <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" spread="0.964"/>
                    <measurement group_id="O2" value="3.99" spread="1.180"/>
                    <measurement group_id="O3" value="3.82" spread="0.957"/>
                    <measurement group_id="O4" value="3.56" spread="0.957"/>
                    <measurement group_id="O5" value="3.69" spread="1.433"/>
                    <measurement group_id="O6" value="3.38" spread="0.907"/>
                    <measurement group_id="O7" value="3.54" spread="0.948"/>
                    <measurement group_id="O8" value="3.75" spread="0.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 5</title>
        <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
        <time_frame>Day 5</time_frame>
        <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 5</title>
          <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
          <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="0.930"/>
                    <measurement group_id="O2" value="3.98" spread="1.269"/>
                    <measurement group_id="O3" value="3.89" spread="1.026"/>
                    <measurement group_id="O4" value="3.53" spread="0.830"/>
                    <measurement group_id="O5" value="3.41" spread="1.242"/>
                    <measurement group_id="O6" value="3.27" spread="1.024"/>
                    <measurement group_id="O7" value="3.32" spread="0.747"/>
                    <measurement group_id="O8" value="3.60" spread="0.969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 7</title>
        <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
        <time_frame>Day 7</time_frame>
        <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 7</title>
          <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
          <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="1.049"/>
                    <measurement group_id="O2" value="4.01" spread="1.297"/>
                    <measurement group_id="O3" value="3.84" spread="0.969"/>
                    <measurement group_id="O4" value="3.58" spread="0.968"/>
                    <measurement group_id="O5" value="3.43" spread="1.378"/>
                    <measurement group_id="O6" value="3.25" spread="0.996"/>
                    <measurement group_id="O7" value="3.32" spread="0.721"/>
                    <measurement group_id="O8" value="3.51" spread="0.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 15</title>
        <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
        <time_frame>Day 15</time_frame>
        <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 15</title>
          <description>Plasma samples were assayed using a validated, sensitive, and specific ICMA fluorescence method.</description>
          <population>Pharmacodynamic analysis set included all participants treated with PF-05231023 or placebo who had at least 1 pharmacodynamic endpoint. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="0.884"/>
                    <measurement group_id="O2" value="3.72" spread="1.166"/>
                    <measurement group_id="O3" value="3.51" spread="0.961"/>
                    <measurement group_id="O4" value="3.25" spread="0.654"/>
                    <measurement group_id="O5" value="3.11" spread="1.135"/>
                    <measurement group_id="O6" value="3.30" spread="0.890"/>
                    <measurement group_id="O7" value="3.20" spread="0.876"/>
                    <measurement group_id="O8" value="3.46" spread="0.920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Cardiac Rhythms Recorded by Telemetry</title>
        <description>Criteria for abnormal cardiac rhythms was based on investigator’s discretion and were reported as adverse event (AE), as planned.</description>
        <time_frame>From 2 hours (H) pre-dose for intravenous bolus or 2 H prior to the start of infusion on Day 1 up to 8 H post-dose for bolus or 8 H following the end of the infusion on Day 1</time_frame>
        <population>Data was not collected since this outcome measure was not analyzed as per Sponsor’s discretion.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Cardiac Rhythms Recorded by Telemetry</title>
          <description>Criteria for abnormal cardiac rhythms was based on investigator’s discretion and were reported as adverse event (AE), as planned.</description>
          <population>Data was not collected since this outcome measure was not analyzed as per Sponsor’s discretion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Time of Last Quantifiable Plasma Concentration (AUClast) of PF-05231023</title>
        <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
Participants who received PF-05231023 with C-terminal and N-terminal AUClast were reported.</description>
        <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
        <population>Pharmacokinetic (PK) parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Time of Last Quantifiable Plasma Concentration (AUClast) of PF-05231023</title>
          <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
Participants who received PF-05231023 with C-terminal and N-terminal AUClast were reported.</description>
          <population>Pharmacokinetic (PK) parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of primary interest.</population>
          <units>ng*hour[H]/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-terminal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="672.3" spread="364.50"/>
                    <measurement group_id="O2" value="2573" spread="475.73"/>
                    <measurement group_id="O3" value="10220" spread="4059.2"/>
                    <measurement group_id="O4" value="29390" spread="6697.4"/>
                    <measurement group_id="O5" value="95120" spread="13749"/>
                    <measurement group_id="O6" value="244200" spread="83895"/>
                    <measurement group_id="O7" value="409300" spread="135030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N-terminal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2957" spread="1887.2"/>
                    <measurement group_id="O2" value="11630" spread="4363.6"/>
                    <measurement group_id="O3" value="47650" spread="10833"/>
                    <measurement group_id="O4" value="168600" spread="50175"/>
                    <measurement group_id="O5" value="564600" spread="161560"/>
                    <measurement group_id="O6" value="121100" spread="386970"/>
                    <measurement group_id="O7" value="280000" spread="756220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05231023</title>
        <description>Participants who received PF-05231023 with C-terminal and N-terminal Tmax were reported.</description>
        <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
        <population>PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05231023</title>
          <description>Participants who received PF-05231023 with C-terminal and N-terminal Tmax were reported.</description>
          <population>PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of primary interest.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-terminal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" lower_limit="0.250" upper_limit="0.533"/>
                    <measurement group_id="O2" value="0.250" lower_limit="0.250" upper_limit="0.500"/>
                    <measurement group_id="O3" value="1.50" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.02" upper_limit="2.53"/>
                    <measurement group_id="O5" value="1.26" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O6" value="1.50" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O7" value="1.02" lower_limit="1.00" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N-terminal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" lower_limit="0.250" upper_limit="3.03"/>
                    <measurement group_id="O2" value="0.250" lower_limit="0.250" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.50" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.02" upper_limit="2.50"/>
                    <measurement group_id="O5" value="1.26" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O6" value="1.50" lower_limit="1.00" upper_limit="2.50"/>
                    <measurement group_id="O7" value="1.50" lower_limit="1.00" upper_limit="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of PF-05231023</title>
        <description>Participants who received PF-05231023 with C-terminal and N-terminal Cmax were reported.</description>
        <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
        <population>PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of PF-05231023</title>
          <description>Participants who received PF-05231023 with C-terminal and N-terminal Cmax were reported.</description>
          <population>PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of primary interest.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-terminal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.7" spread="40.994"/>
                    <measurement group_id="O2" value="347.9" spread="61.165"/>
                    <measurement group_id="O3" value="1360" spread="1264.9"/>
                    <measurement group_id="O4" value="3324" spread="656.74"/>
                    <measurement group_id="O5" value="11730" spread="4857.6"/>
                    <measurement group_id="O6" value="28740" spread="8031.1"/>
                    <measurement group_id="O7" value="47780" spread="13784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N-terminal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.0" spread="44.923"/>
                    <measurement group_id="O2" value="393.2" spread="75.603"/>
                    <measurement group_id="O3" value="1199" spread="386.56"/>
                    <measurement group_id="O4" value="3693" spread="714.42"/>
                    <measurement group_id="O5" value="14180" spread="3928.7"/>
                    <measurement group_id="O6" value="28850" spread="6375.5"/>
                    <measurement group_id="O7" value="61910" spread="8125.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Terminal Half-Life (t1/2) of PF-05231023</title>
        <description>Plasma terminal half-life is the time measured for the plasma concentration to decrease by one half at the terminal phase. Participants who received PF-05231023 with C-terminal and N-terminal t1/2 were reported.</description>
        <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
        <population>PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of primary interest. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.'n' signifies participants who were evaluable for each specified parameter for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Terminal Half-Life (t1/2) of PF-05231023</title>
          <description>Plasma terminal half-life is the time measured for the plasma concentration to decrease by one half at the terminal phase. Participants who received PF-05231023 with C-terminal and N-terminal t1/2 were reported.</description>
          <population>PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of primary interest. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.'n' signifies participants who were evaluable for each specified parameter for each arm, respectively.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-terminal (n=2,10,10,9,10,10,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported since less than 3 participants were evaluable.</measurement>
                    <measurement group_id="O2" value="6.504" spread="1.0814"/>
                    <measurement group_id="O3" value="7.168" spread="1.2433"/>
                    <measurement group_id="O4" value="7.143" spread="1.5009"/>
                    <measurement group_id="O5" value="7.748" spread="1.1304"/>
                    <measurement group_id="O6" value="7.502" spread="0.9999"/>
                    <measurement group_id="O7" value="7.302" spread="1.7117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N-terminal (n=7,9,10,10,9,10,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.49" spread="6.5685"/>
                    <measurement group_id="O2" value="37.64" spread="9.0438"/>
                    <measurement group_id="O3" value="66.54" spread="12.792"/>
                    <measurement group_id="O4" value="77.39" spread="11.979"/>
                    <measurement group_id="O5" value="81.52" spread="12.599"/>
                    <measurement group_id="O6" value="87.69" spread="16.556"/>
                    <measurement group_id="O7" value="96.64" spread="8.0925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL) of PF-05231023 for Intravenous Bolus Dosing</title>
        <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.Participants who received PF-05231023 with C-terminal and N-terminal CL were reported.</description>
        <time_frame>Hour (H)-1 (1 H pre-dose to bolus [Bo]),H-0.5(0.5 H pre-dose to Bo),H 0 (prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
        <population>PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of primary interest. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. 'n' signifies participants who were evaluable for each specified parameter for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL) of PF-05231023 for Intravenous Bolus Dosing</title>
          <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.Participants who received PF-05231023 with C-terminal and N-terminal CL were reported.</description>
          <population>PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of primary interest. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. 'n' signifies participants who were evaluable for each specified parameter for each arm, respectively.</population>
          <units>liter per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-terminal (n=2,10,10,9,10,10,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported since less than 3 participants were evaluable.</measurement>
                    <measurement group_id="O2" value="0.5368" spread="0.0972"/>
                    <measurement group_id="O3" value="0.4642" spread="0.15736"/>
                    <measurement group_id="O4" value="0.4974" spread="0.12295"/>
                    <measurement group_id="O5" value="0.5245" spread="0.0892"/>
                    <measurement group_id="O6" value="0.4092" spread="0.12015"/>
                    <measurement group_id="O7" value="0.4883" spread="0.25652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N-terminal (n=7,9,10,10,9,10,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1057" spread="0.0459"/>
                    <measurement group_id="O2" value="0.1282" spread="0.0417"/>
                    <measurement group_id="O3" value="0.1014" spread="0.0203"/>
                    <measurement group_id="O4" value="0.0879" spread="0.03216"/>
                    <measurement group_id="O5" value="0.08611" spread="0.02916"/>
                    <measurement group_id="O6" value="0.08050" spread="0.0256"/>
                    <measurement group_id="O7" value="0.07021" spread="0.0186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz) of PF-05231023</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. PF-05231023 with C-terminal and N-terminal Vz were reported.</description>
        <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
        <population>PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of primary interest. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. 'n' signifies participants who were evaluable for each specified parameter for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz) of PF-05231023</title>
          <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. PF-05231023 with C-terminal and N-terminal Vz were reported.</description>
          <population>PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of primary interest. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. 'n' signifies participants who were evaluable for each specified parameter for each arm, respectively.</population>
          <units>Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-terminal (n=2,10,10,9,10,10,10 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported since less than 3 participants were evaluable.</measurement>
                    <measurement group_id="O2" value="4.977" spread="0.93206"/>
                    <measurement group_id="O3" value="4.741" spread="1.1834"/>
                    <measurement group_id="O4" value="5.029" spread="0.81502"/>
                    <measurement group_id="O5" value="5.799" spread="1.5559"/>
                    <measurement group_id="O6" value="4.397" spread="1.1511"/>
                    <measurement group_id="O7" value="5.014" spread="1.2498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N-terminal (n=7,9,10,10,9,10,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.709" spread="0.82966"/>
                    <measurement group_id="O2" value="6.758" spread="1.1934"/>
                    <measurement group_id="O3" value="9.526" spread="2.2753"/>
                    <measurement group_id="O4" value="9.704" spread="2.1259"/>
                    <measurement group_id="O5" value="10.01" spread="2.9519"/>
                    <measurement group_id="O6" value="9.979" spread="2.7792"/>
                    <measurement group_id="O7" value="9.767" spread="2.5208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-05231023</title>
        <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). PF-05231023 with C-terminal and N-terminal AUC (0 - ∞) were reported.</description>
        <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
        <population>PK parameter analysis set included all participants randomized and treated who have at least 1 of the PK parameters of primary interest. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. 'n' signifies participants who were evaluable for each specified parameter for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-05231023</title>
          <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). PF-05231023 with C-terminal and N-terminal AUC (0 - ∞) were reported.</description>
          <population>PK parameter analysis set included all participants randomized and treated who have at least 1 of the PK parameters of primary interest. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. 'n' signifies participants who were evaluable for each specified parameter for each arm, respectively.</population>
          <units>ng*hr/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-terminal (n=2,10,10,9,10,10,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported since less than 3 participants were evaluable.</measurement>
                    <measurement group_id="O2" value="2793" spread="557.86"/>
                    <measurement group_id="O3" value="10770" spread="3999.8"/>
                    <measurement group_id="O4" value="30140" spread="7079.3"/>
                    <measurement group_id="O5" value="95350" spread="13817"/>
                    <measurement group_id="O6" value="244300" spread="84238"/>
                    <measurement group_id="O7" value="409700" spread="135300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N-terminal (n=7,9,10,10,9,10,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4726" spread="1594.5"/>
                    <measurement group_id="O2" value="11700" spread="4305.5"/>
                    <measurement group_id="O3" value="49340" spread="10835"/>
                    <measurement group_id="O4" value="170600" spread="50735"/>
                    <measurement group_id="O5" value="581000" spread="168820"/>
                    <measurement group_id="O6" value="1241000" spread="395290"/>
                    <measurement group_id="O7" value="2848000" spread="779810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Back-extrapolated Concentration at Time Zero (C0) of PF-05231023</title>
        <description>C0 was estimated by back-extrapolating from the first 2 concentration values using the log-linear regression on the first 2 data points (where second concentration was less than [&lt;] first concentration) to back-extrapolate C0. PF-05231023 with C-terminal and N-terminal C0 were reported.</description>
        <time_frame>0.25 H post-dose to Bo on Day 1</time_frame>
        <population>PK parameter analysis set included all participants randomized and treated who have at least 1 of the PK parameters of primary interest. C0 was calculated for cohort 1 (group: PF-05231023 0.5 mg) and 2 (group: PF-05231023 1.5 mg) only as per planned analysis, hence results for the same reported.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Back-extrapolated Concentration at Time Zero (C0) of PF-05231023</title>
          <description>C0 was estimated by back-extrapolating from the first 2 concentration values using the log-linear regression on the first 2 data points (where second concentration was less than [&lt;] first concentration) to back-extrapolate C0. PF-05231023 with C-terminal and N-terminal C0 were reported.</description>
          <population>PK parameter analysis set included all participants randomized and treated who have at least 1 of the PK parameters of primary interest. C0 was calculated for cohort 1 (group: PF-05231023 0.5 mg) and 2 (group: PF-05231023 1.5 mg) only as per planned analysis, hence results for the same reported.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-terminal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.7" spread="47.581"/>
                    <measurement group_id="O2" value="363.0" spread="81.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N-terminal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.8" spread="47.543"/>
                    <measurement group_id="O2" value="415.4" spread="81.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Vss) of PF-05231023</title>
        <description>Vss was calculated by dividing the area under the first moment curve from time zero to infinity [AUMC(0-∞)] with the product of area under the curve from time zero to extrapolated infinite time [AUC (0 - ∞)] and apparent clearance (CL). PF-05231023 with C-terminal and N-terminal Vss were reported.</description>
        <time_frame>Hour(H)-1(prior to start of infusion[In] or 1 H pre-dose to bolus[Bo]),H-0.5(0.5 H post start of In or 0.5 H pre-dose to Bo),H 0(end of In or prior to Bo),0.25,0.5,1,1.5,2,3,5,8,12 H post end of In or post-dose to Bo on Day 1;Day 2,3,4,5,6,8,15,22</time_frame>
        <population>PK parameter analysis set included all participants randomized and treated who have at least 1 of the PK parameters of primary interest. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. 'n' signifies participants who were evaluable for each specified parameter for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05231023 0.5 mg</title>
            <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-05231023 1.5 mg</title>
            <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05231023 5 mg</title>
            <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05231023 15 mg</title>
            <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05231023 50 mg</title>
            <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-05231023 100 mg</title>
            <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>PF-05231023 200 mg</title>
            <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss) of PF-05231023</title>
          <description>Vss was calculated by dividing the area under the first moment curve from time zero to infinity [AUMC(0-∞)] with the product of area under the curve from time zero to extrapolated infinite time [AUC (0 - ∞)] and apparent clearance (CL). PF-05231023 with C-terminal and N-terminal Vss were reported.</description>
          <population>PK parameter analysis set included all participants randomized and treated who have at least 1 of the PK parameters of primary interest. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. 'n' signifies participants who were evaluable for each specified parameter for each arm, respectively.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-terminal (n=2,10,10,9,10,10,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported since less than 3 participants were evaluable.</measurement>
                    <measurement group_id="O2" value="4.897" spread="0.9277"/>
                    <measurement group_id="O3" value="4.596" spread="1.2589"/>
                    <measurement group_id="O4" value="5.023" spread="0.96722"/>
                    <measurement group_id="O5" value="5.650" spread="1.9178"/>
                    <measurement group_id="O6" value="4.082" spread="1.1896"/>
                    <measurement group_id="O7" value="4.655" spread="1.0748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N-terminal (n=7,9,10,10,9,10,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.544" spread="0.81713"/>
                    <measurement group_id="O2" value="6.151" spread="1.1762"/>
                    <measurement group_id="O3" value="7.165" spread="1.4032"/>
                    <measurement group_id="O4" value="7.322" spread="1.2447"/>
                    <measurement group_id="O5" value="7.022" spread="1.4714"/>
                    <measurement group_id="O6" value="7.004" spread="1.4774"/>
                    <measurement group_id="O7" value="7.197" spread="1.4347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>PF-05231023 0.5 mg</title>
          <description>Single dose of PF-05231023 0.5 milligram (mg) intravenous bolus injection on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>PF-05231023 1.5 mg</title>
          <description>Single dose of PF-05231023 1.5 mg, intravenous bolus injection on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>PF-05231023 5 mg</title>
          <description>Single dose of PF-05231023 5 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>PF-05231023 15 mg</title>
          <description>Single dose of PF-05231023 15 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>PF-05231023 50 mg</title>
          <description>Single dose of PF-05231023 50 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>PF-05231023 100 mg</title>
          <description>Single dose of PF-05231023 100 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>PF-05231023 200 mg</title>
          <description>Single dose of PF-05231023 200 mg intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
        <group group_id="E8">
          <title>Placebo</title>
          <description>Single dose of placebo matched to either intravenous bolus injection or intravenous infusion over approximately 1 hour on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Results for C0 and Vss was included as secondary endpoints as per change in the planned analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

